Figure 7.

Neoadjuvant therapy of CBDCA and anti-PD-1 antibodies increases the frequencies of CD103⁺ dendritic cells (DC) and CCL4-producing tumor cells in secondary breast cancers. Secondary tumors were collected at Day 35 after the primary tumor implantation. (A) Immunofluorescence staining of CD103 and CCL4 in tumors. Scale bar: 9 μm. (B) Gating strategies for DC, which were defined as CD45⁺MHCII⁺CD11c⁺CD11b^dim cells. (C) Treatment of CBDCA plus anti-PD-1 antibodies as a neoadjuvant therapeutic regimen increased the ratio of CD103⁺ DC in implanted TNBC tumors. n = 8 per group from one of triplicated experiments. (D) Flow cytometry analysis of CCL4-producing cells. (E) Treatment of CBDCA and anti-PD-1 antibodies increased the proportion of CD45⁻CCL4⁺ cells in implanted TNBC tumors. n = 8 per group from one of triplicated experiments. **p < 0.01; ***p < 0.001, by two-tail student t-tests.